<table>
<thead>
<tr>
<th>Title</th>
<th>Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells (Dissertation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Noma, Naruto</td>
</tr>
<tr>
<td>Citation</td>
<td>Kyoto University (京都大学)</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2017-03-23</td>
</tr>
<tr>
<td>URL</td>
<td><a href="https://doi.org/10.14989/doctor.k20221">https://doi.org/10.14989/doctor.k20221</a></td>
</tr>
<tr>
<td>Type</td>
<td>Thesis or Dissertation</td>
</tr>
<tr>
<td>Textversion</td>
<td>ETD</td>
</tr>
</tbody>
</table>

This is the peer-reviewed but unedited manuscript version of the following article: Int Arch Allergy Immunol 2015;166:84-90 (DOI:10.1159/000371419). The final, published version is available at http://www.karger.com/?doi=371419
Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells

Naruto Noma a Masataka Asagiri a Masatoshi Takeiri a Saori Ohmae a Kenji Takemoto a,b Keiko Iwaisako c Mari Maeda-Yamamoto e Nagahiro Minato d Siro Simizu f Kazuo Umezawa g

a Innovation Center for Immunoregulation and Therapeutics, b Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery and Departments of Target Therapy Oncology and Immunology and Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, c Food Function Division, National Food Research Institute, National Agriculture and Food Research Organization, Tsukuba, d Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, and e Department of Molecular Target Medicine Screening, Aichi Medical University School of Medicine, Nagakute, Japan

Key Words
(–)-DHMEQ · NF-κB · MMP-2 · Invasion · Mast cell

Abstract
Background: Stimulation with antigen and IgE is known to activate NF-κB in mast cells. In the present research, we studied the role of NF-κB on cellular migration in mast cell-like RBL-2H3 cells and bone marrow-derived mast cells (BMMCs) using the NF-κB inhibitor (–)-DHMEQ. Methods: A Matrigel invasion chamber was used to evaluate cell migration. A PCR array was used to screen the expression of 84 key genes involved in cell migration. Results: (–)-DHMEQ inhibited antigen/IgE-induced NF-κB activation and expressions of its target genes such as IL-6 and TNF-α. (–)-DHMEQ was found to inhibit in vitro invasion toward the antigen without any toxicity. We then looked for NF-κB-dependent genes that would be important for mast cell invasion using the PCR array. (–)-DHMEQ was found to lower the expression of matrix metalloproteinase (MMP-2). The MMP inhibitor GM6001 also inhibited cellular invasion toward the antigen. These effects of (–)-DHMEQ were obtained in both RBL-2H3 cells and BMMCs.

Conclusions: These findings indicate that (–)-DHMEQ suppressed mast cell migration via the inhibition of NF-κB-regulated MMP-2 expression.

Introduction
Bronchial asthma, urticaria, angioedema, allergic rhinitis, and allergic conjunctivitis are all caused by type I allergic reactions. Type I allergic reaction is mediated by antigen-specific IgE-binding mast cell degranulation [1], and this reaction leads to anaphylactic shock when it takes place in the whole body [2]. Mast cells secrete leukotrienes, histamine and prostaglandins upon activation with antigen and IgE and play a central role in allergic reactions [3]. Allergic inflammation is characterized by tissue infiltration of inflamma-
tory cells, including mast cells, lymphocytes and eosinophils [4]. It has previously been shown that rat basophilic leukemia RBL-2H3 cells sensitized with antigen-specific IgE migrate toward the antigen, and this migration is directional [4]. Moreover, mast cell invasion is not only involved in inflammation but also in cancer malignancy [5].

Activation of the FcεRI receptor in mast cells induces the IKK-NF-κB pathway [6]. NF-κB activation mediated by IgE/DNP induces the expression of inflammatory cytokines such as TNF and IL-6 in RBL-2H3 cells [7]. In cancer cells, NF-κB activation also induces cell migration and invasion by inducing matrix metalloproteinase (MMP-9), urokinase-type plasminogen activator and ICAM-1 [8]. On the other hand, the relationship between NF-κB activation and the motility of mast cells is unknown.

Previously, we designed and synthesized a novel NF-κB inhibitor, (−)-dehydroxymethylepoxyquinomicin, called (−)-DHMEQ (fig. 1a) [9]. DHMEQ is synthesized as its racemic form, and after chiral separation the (−)-DHMEQ enantiomer is about 10 times stronger than the (+)-DHMEQ enantiomers [10]. (−)-DHMEQ inhibits the translocation of NF-κB protein to the nucleus [11] and DNA binding activity of NF-κB by covalently binding to specific cysteine residues of the protein [12]. (−)-DHMEQ showed various anti-inflammatory effects on animal models, including rheumatoid arthritis [13] and renal inflammation [14].

In the present research, we found that the NF-κB inhibitor (−)-DHMEQ inhibited IgE-sensitized cell invasion in mast cell-like RBL-2H3 cells and mouse bone marrow-derived mast cells and revealed the inhibitory mechanism.

Materials and Methods

Materials

(−)-DHMEQ was synthesized in our laboratory as previously described [10]. DNP-albumin conjugate, bovine, pan-MMP inhibitor GM6001 and the selective MMP-2 inhibitor cis-9-octadecenoic acid-N-hydroxylamide (OA-Hy), were purchased from Calbiochem (Darmstadt, Germany). Monoclonal anti-dinitrophenyl antibody IgE SPE-7 and anti-MMP-2 antibody were purchased from Sigma (St. Louis, Mo., USA) and Daiichi Fine Chemical (Toyama, Japan), respectively.

Cell Culture

Rat basophilic leukemia RBL-2H3 cells were maintained in Dulbecco’s modified Eagle’s medium (Nissui Pharmaceutical Co. Ltd., Tokyo, Japan) supplemented with 10% (v/v) heat-inactivated FBS, 200 U/ml penicillin G, 200 mg/l kanamycin, 600 mg/l L-glutamine, and 2.25 g/l NaHCO3 at 37°C in a humidified incubator with 5% CO2. Mouse bone marrow-derived mast cells (BMMCs) were generated from 6-week-old C57BL/6 mice according to the method described previously [15]. Briefly, bone marrow cells in alpha modification of Eagle’s medium (α-MEM; Invitrogen, Carlsbad, Calif., USA) containing 10% FBS, 100 U/ml penicillin G, 100 μg/ml streptomycin, 1 mM sodium pyruvate, 0.1 mM nonessential amino acid, and 50 μM 2-mercaptoethanol (Invitrogen) supplemented with 10 ng/ml mIL-3 (PeproTech, Rocky Hill, N.J., USA) were cultured at 37°C in a humidified atmosphere of 5% CO2. Nonadherent cells were transferred every week for up to 4 weeks into fresh culture medium. BMMCs were used when >95% of the cells were mast cells determined by flow cytometry for FcεRI expression and by toluidine blue staining.

Cellular Invasion through Matrigel

Assays were performed using a 24-well Matrigel invasion chamber with a pore size of 8.0 μm (BD Biosciences, Bedford, MA) [16] or 24-well cell culture inserts with 8-μm pore size filters (BD Biosciences) coated with 100 μl of Matrigel (BD Biosciences) to form a thin continuous layer and allowed to solidify at 37°C for 1 h [17]. The lower compartment was filled with 500 μl of the serum-free medium, with or without the indicated concentration of DNP-BSA. RBL-2H3 cells (2.0 × 105) or BMMCs (1.0 × 106) were resuspended in 500 μl of the same medium and placed in the upper part of the Matrigel plate. The cells were incubated for 24 h and then fixed and stained. Cells on the upper surface of the filter were removed mechanically by wiping with a cotton swab and, under light microscopic observation, the invasive phenotypes were determined by counting the cells that had migrated to the lower side of the filter. Three randomly selected fields were counted from each well and experiments were repeated 3 times. Cell growth was measured with Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) as previously described [18].

Electrophoretic Mobility Shift Assay

An electrophoretic mobility shift assay for NF-κB binding to DNA was carried out as described [12]. The DNA probes used for NF-κB binding were double-stranded oligonucleotides (5′-GAC AGAGGGGACTTTTCCGAGAG-3′) used in a previous report [19].

RNA Isolation and Semiquantitative RT-PCR Analysis

Total RNA was extracted from RBL-2H3 cells using TRizol reagent (Invitrogen). Reverse transcription was carried out with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, Calif., USA). The cDNA was used for PCR amplification with rTaq DNA polymerase (Takara Bio, Shiga, Japan). The sequences of the primers used for semiquantitative RT-PCR, the numbers of cycles and the annealing temperatures are shown in online supplementary table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000371419).

Real-Time PCR Array

Total RNA was extracted from RBL-2H3 cells using RNeasy mini (Qiagen, Hilden, Germany). Reverse transcription was carried out at 42°C for 15 min with the RT2 First Strand Kit (Qiagen). The cDNA was used for PCR amplification with RT2 SYBR Green ROX qPCR Master Mix (Qiagen). The cDNA was added to the qPCR Master Mix and the aliquot mixture across the Rat Cell Motility PCR Array (Qiagen). Hprt1 was used as a housekeeping gene. Data analysis was carried out by the ΔΔCt method.
Results

Inhibition of NF-κB and Migration by (–)-DHMEQ in RBL-2H3 Cells

IgE/DNP-BSA-induced NF-κB activation was inhibited by (–)-DHMEQ (fig. 1a) in rat mast cell-like RBL-2H3 cells at its nontoxic concentrations (fig. 1b). It also inhibited NF-κB downstream genes such as TNF-α and IL-6 (fig. 1c). Moreover, (–)-DHMEQ was found to inhibit the migration of IgE-sensitized RBL-2H3 cells toward the antigen in a Matrigel chamber assay without any toxicity (fig. 1d).
Inhibition of MMP-2 Expression by (–)-DHMEQ

We next searched for critical factors responsible for cell invasion that are regulated by NF-κB. Then, we searched for those specific genes using a real-time PCR array system arranged for cell motility. RBL-2H3 cells were treated with IgE/DNP with or without (–)-DHMEQ. We then compared the gene expression of (–)-DHMEQ-treated and untreated cells. We evaluated 84 genes related to cell motility. Expressions of cell motility-related genes such as MMP-2, Pak4 and Akt1 were lowered by (–)-DHMEQ, as shown in table 1. Among them, we focused on MMP-2 expression in RBL-2H3 cells and analyzed it by semiquantitative RT-PCR. (–)-DHMEQ inhibited IgE/DNP-induced MMP-2 expression in a dose-dependent manner, while it did not inhibit MMP-13 and MT1-MMP expression in RBL-2H3 cells (fig. 2a).

Table 1. Motility-related genes downregulated by (–)-DHMEQ

<table>
<thead>
<tr>
<th>Protein names</th>
<th>Expression level (% of control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMP-2</td>
<td>22.2</td>
</tr>
<tr>
<td>Pak4</td>
<td>41.2</td>
</tr>
<tr>
<td>Akt1</td>
<td>49.3</td>
</tr>
<tr>
<td>Cfl1</td>
<td>51.1</td>
</tr>
<tr>
<td>Diaph1</td>
<td>55.5</td>
</tr>
<tr>
<td>IGF-1</td>
<td>56.3</td>
</tr>
<tr>
<td>Cav1</td>
<td>57.4</td>
</tr>
<tr>
<td>Arhgef7</td>
<td>62.0</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>62.4</td>
</tr>
<tr>
<td>Vcl</td>
<td>62.9</td>
</tr>
</tbody>
</table>

RBL-2H3 cells were treated as described in Materials and Methods. The top 10 genes downregulated by (–)-DHMEQ (10 μg/ml) are listed.

Inhibition of Cellular Invasion by MMP Inhibitor GM6001

Next we studied whether MMP-2 is involved in RBL-2H3 invasion, and employed the MMP inhibitor GM6001, which is known to inhibit MMP-2 [20]. GM6001 inhibited IgE-sensitized cell invasion toward the antigen in RBL-2H3 cells, as shown in figure 3a. Moreover, cotreatment with GM6001 and (–)-DHMEQ did not show additive inhibition compared with (–)-DHMEQ alone or GM6001 alone (fig. 3a). In addition, the selective MMP-2 inhibitor OA-Hy also inhibited RBL-2H3 cell invasion, although this chemical is slightly toxic (fig. 3b).

Inhibition of Cellular Invasion and MMP-2 Expression by (–)-DHMEQ in Primary Culture Mouse Mast Cells

We prepared a primary culture of mouse mast cells, as described in Methods. We then studied the effect of (–)-DHMEQ on NF-κB activity, MMP-2 expression and Matrigel invasion in these cells. (–)-DHMEQ inhib-
NF-κB plays a central role in allergic inflammation, since it promotes the transcription of Th2 cytokines such as IL-6. Treatment with NF-κB decoy oligodeoxynucleotides inhibits atopic dermatitis in the NC/Nga atopic mouse model, and this inhibition is accompanied by a significant decrease in the infiltration of mast cells into the dermis [21]. Moreover, ointment containing DHMEQ improves atopic dermatitis manifestation in mice, with an efficacy equivalent to that of tacrolimus or betamethasone [22]. DHMEQ inhibited mast cell accumulation in the inflammatory site in this experiment [22]. Thus, it is likely to inhibit mast cell activity by inhibition of its invasion in animal experiments (fig. 1d).

We identified MMP-2 as a new target gene of NF-κB in rat basophilic leukemia RBL-2H3 cells. It is reported that the NF-κB complex is composed of a heterodimer of p65 and p50 when activated by IgE/DNP-BSA in RBL-2H3 cells [19]. We observed that the band of NF-κB was weakened by treatment with either anti-p65 antibody or anti-RelB antibody in IgE/DNP-BSA-treated RBL-2H3 cells in the electrophoretic mobility shift assay (data not shown). Therefore, it is likely that both canonical and noncanonical NF-κB activation pathways would be activated in RBL-2H3 cells.

The PCR array demonstrated that (−)-DHMEQ decreased the expression of several cell motility-related genes in RBL-2H3 cells (table 1). We focused on MMP-2 because the expression of MMP-2 has been linked with tumor invasion, angiogenesis and metastasis [23], and MMPs appear to be involved in allergic inflammation [24]. MMP-2 was detected in RBL-2H3 cells [25], but its role in RBL-2H3 cells remains to be revealed.

We investigated the regulation of MMP-2 mRNA transcription by luciferase promoter analysis. The rat MMP-2 promoter has an NF-κB consensus binding site

Discussion

NF-κB plays a central role in allergic inflammation, since it promotes the transcription of Th2 cytokines such as IL-6. Treatment with NF-κB decoy oligodeoxynucleotides inhibits atopic dermatitis in the NC/Nga atopic mouse model, and this inhibition is accompanied by a significant decrease in the infiltration of mast cells into the dermis [21]. Moreover, ointment containing DHMEQ improves atopic dermatitis manifestation in mice, with an efficacy equivalent to that of tacrolimus or betamethasone [22]. DHMEQ inhibited mast cell accumulation in the inflammatory site in this experiment [22]. Thus, it is likely to inhibit mast cell activity by inhibition of its invasion in animal experiments (fig. 1d).
Noma et al. Int Arch Allergy Immunol
DOI: 10.1159/000371419

6

(–823 to –813 bp). However, the MMP-2 promoter region from 1,000 bp upstream to 83 bp downstream did not affect promoter activity in the deletion analysis. Thus, the upregulation of MMP-2 by IgE/DNP would be mediated by the complex of NF-κB and other transcription factors such as Sp-1 and C/EBPββ that bind to another MMP-2 promoter site.

Thus, mast cell trafficking should also be regulated by IgE-independent triggers with various cytokines. Involvement of NF-κB in these IgE-independent mechanisms remains to be studied.

In conclusion, our findings indicate that (–)-DHMEQ suppressed mast cell migration via the inhibition of NF-κB-regulated MMP-2 expression. (–)-DHMEQ may be a candidate as an antiallergy agent inhibiting mast cell accumulation.

Acknowledgments

This work was supported in part by grants from the Grants-in-Aid for Scientific Research programs (grant B 23310163 to K.U. and grants 24659822 and 24689056 to M.A.) from MEXT and the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and by the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, Aichi Medical University for the years 2011–2015 (S1101027).

References

MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ


